DexCom, Inc. (NASDAQ:DXCM) had its price objective reduced by Oppenheimer Holdings, Inc. from $92.00 to $85.00 in a research note released on Thursday morning. They currently have an outperform rating on the medical device company’s stock. Oppenheimer Holdings also issued estimates for DexCom’s Q4 2017 earnings at $0.06 EPS.

Several other equities research analysts have also recently weighed in on DXCM. Canaccord Genuity reissued a buy rating and issued a $90.00 price objective on shares of DexCom in a research report on Wednesday, June 7th. BidaskClub raised DexCom from a sell rating to a hold rating in a research report on Thursday, June 15th. Piper Jaffray Companies reissued a buy rating and issued a $78.00 price objective on shares of DexCom in a research report on Wednesday, July 12th. BMO Capital Markets reissued a buy rating and issued a $105.00 price objective on shares of DexCom in a research report on Thursday, July 13th. Finally, Cowen and Company reissued a buy rating and issued a $90.00 price objective on shares of DexCom in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $72.19.

Shares of DexCom (DXCM) traded up 7.669% during mid-day trading on Thursday, hitting $48.925. 9,357,971 shares of the company were exchanged. The stock’s market cap is $4.23 billion. DexCom has a 12-month low of $45.61 and a 12-month high of $94.24. The stock’s 50-day moving average price is $72.62 and its 200 day moving average price is $73.86.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. During the same period in the prior year, the business earned ($0.24) earnings per share. DexCom’s revenue for the quarter was up 24.3% compared to the same quarter last year. On average, equities analysts anticipate that DexCom will post ($0.79) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Oppenheimer Holdings, Inc. Trims DexCom, Inc. (DXCM) Target Price to $85.00” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.watchlistnews.com/oppenheimer-holdings-inc-trims-dexcom-inc-dxcm-target-price-to-85-00/1600972.html.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $71.86, for a total transaction of $431,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction on Monday, July 10th. The stock was sold at an average price of $71.55, for a total value of $228,960.00. The disclosure for this sale can be found here. Insiders have sold 32,223 shares of company stock valued at $2,285,138 over the last quarter. Corporate insiders own 1.70% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in DXCM. Janus Henderson Group PLC raised its stake in DexCom by 101,699.8% during the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after acquiring an additional 6,822,023 shares in the last quarter. BlackRock Inc. raised its stake in DexCom by 5,000.4% during the first quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock worth $352,550,000 after acquiring an additional 4,079,283 shares in the last quarter. Winslow Capital Management LLC acquired a new position in DexCom during the second quarter worth $117,451,000. FMR LLC raised its stake in DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after acquiring an additional 978,898 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in DexCom by 27.3% during the second quarter. Bank of New York Mellon Corp now owns 3,242,928 shares of the medical device company’s stock worth $237,221,000 after acquiring an additional 696,199 shares in the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.